The Novo Reset: A Prescription for Success in a Crowded Market

The pharmaceutical industry is marked by high-stakes deals, aggressive marketing campaigns, and cutting-edge research and development. When Novo Nordisk A/S (NYSE:NVO) announced its plan to rebrand as “Novo” and undertake a cultural reset, it was clear that the company’s motivations went beyond cosmetic changes.

The move is partly a response to increasing pressure from Eli Lilly, which has been rapidly narrowing the gap in the obesity-drug market. Novo still holds a dominant position in global obesity-market share, but its diabetes value-market share has fallen significantly. The numbers are telling: in 2025, Novo generated DKK 309.1 billion of sales and DKK 127.7 billion of operating profit, with obesity-care sales rising 31% at constant exchange rates to DKK 82.3 billion.

However, the company also spent around DKK 8 billion on its transformation in 2025, a significant investment that underscores the need for change. Novo’s cultural reset is not merely a matter of throwing money at the problem or slapping a new label on the same old strategies. Rather, it represents an attempt to inject momentum into the company’s operations, allowing it to convert its scientific and commercial assets into faster growth.

The success of this effort will depend on Novo’s ability to reduce internal bureaucracy, streamline decision-making, and accelerate R&D. If the reorganization can deliver these benefits, it could help Novo extract more value from its existing obesity portfolio while advancing next-generation treatments before the semaglutide patent cliff expected early next decade.

Wegovy, Novo’s flagship product, is a key asset that the reset will build around. With approval in 52 countries and impressive Phase 3 study results – including a 20.7% weight loss from the higher-dose formulation – Wegovy has already demonstrated its commercial potential. The recent approval of Wegovy in China for MASH represents a significant milestone in Novo’s efforts to build momentum around its obesity pipeline.

By combining these products with better execution, the reset could support higher patient volumes and extend the commercial life of its GLP-1 franchise, helping defend revenue and cash flow despite pricing pressure. The pharmaceutical industry is a high-stakes game, where the failure to innovate can have far-reaching consequences. Novo’s cultural reset represents an acknowledgment that the company cannot simply rely on its existing assets or maintain the status quo in the face of increasing competition from Lilly and other players.

By investing heavily in R&D and accelerating decision-making, Novo is placing a bet on its ability to adapt and innovate in a rapidly changing market. If successful, this effort could yield significant rewards – not just for Novo, but also for patients who stand to benefit from the company’s innovative treatments. As the industry continues to evolve and consolidate, companies will need to demonstrate their ability to adapt and innovate in order to remain competitive.

Novo’s reset has implications that extend far beyond the company itself. Companies will need to stay nimble and responsive to changing market conditions to remain competitive. In an industry where the stakes are high and the margins are thin, those that fail to invest in innovation and adaptability risk being left behind. By watching how Novo navigates its reset, we may gain valuable insights into what it takes to succeed – and what pitfalls to avoid – in this complex landscape.

Ultimately, only companies willing to take bold action and invest in innovation will be able to thrive in a crowded market. Novo’s reset represents a critical moment of truth for the company, its competitors, and the patients who stand to benefit from their innovative treatments.